Cambridge and Peterborough
PHM at Scale – Statin Optimisation
In partnership with Cambridge & Peterborough ICB and ECLIPSE
(Equality of Care Led Insights for Patient Safety & Engagement)
Practice Pro-Forma
Project overview:
To familiarise practices with the upcoming Population Health Management (PHM) at Scale programme starting April 2024, practices are being offered a complimentary module to improve their attainment of the CHOL001 QOF indicator 2023/24.
We would like to invite you to complete an expression of interest and provide your practice permissions for the CHOL001 statin optimisation pathway within Eclipse.
This offers support for your practice to conduct a statin optimisation programme to increase statin uptake, which will contribute towards your QOF for 2023-24 for indicator CHOL001:
This offer is available immediately and will run up until the end of the QOF year 2023/24.
WHY: Individuals who have already had a Major Cardiovascular Adverse Event (MACE) and are coded on the practice QOF registers are expected to have lipid lowering therapy offered to them. The national ambition is that 95% of such individuals are on some form of lipid lowering therapy. Informed patients can always decline and this needs to be coded in their record.
Given the current pressures on GP practices, the ICB are keen to support your practice in improving statin uptake amongst these eligible patient groups, while minimising additional workload for the workforce.
HOW: The solution being offered utilises Eclipse’s digital patient engagement platform which will automatically identify your eligible patients, engage with them via SMS, educate and counsel them using a lander page and consenting them for statin initiation (or alternative lipid lowering therapy) via access to their secure questionnaire portal.
Eclipse will segment this population into different cohorts for you to consider prescribing a statin, ezetimibe, or decline lipid lowering therapy.
COHORTS: The cohort will be those missing on your CHOL001 QOF indicator, to directly support your practice payments. These will be those who already have established cardiovascular disease, including those coded with a cardiovascular event (ischaemic heart disease, stroke/TIA, peripheral arterial or vascular disease).
Please note that the prescription will be at the clinical discretion of the practice’s own prescriber(s).
EVALUATION: As well as quantitative data, which will be collected via Eclipse, patient reported outcomes and perceptions of the new pathway will be collected through patient questionnaires.
If your practice would like to take part: Please complete the below pro forma, expressing your interest and permissions for patient engagement.
Please note that you will be notified prior to any active patient engagement, and your practice will be issued with a guide on how to view patient lists and document patient reviews.